Exelixis | EXEL - ايرادات المبيعات





مبيعات تغيير تاريخ
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.38B 90M 2026-06
Bayer EUR 13.41B 1.97B 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Cytokinetics USD 19.35M 1.59M 2026-03
Eisai JPY 234.33B 28.9B 2026-06
Eli Lilly USD 19.8B 500M 2026-03
Exelixis USD 610.8M 12.14M 2026-03
Genmab DKK 1.06B 36M 2025-12
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.29B 110M 2026-03
Moderna USD 100M 289M 2026-06
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 14.5B 3.08B 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.14B 65M 2026-03
Takeda JPY 1.22T 130B 2026-06
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Xencor USD 4.51M 23.73M 2026-03